Clinical Trial Update: Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating conversion therapy with Fruquintinib plus Sintilimab and the SOX regimen in unresectable gastric cancer is currently active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)
• Sintilimab (sintilimab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Gastric Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING